Skip to content

IPF Evaluation: Discussing the way forward

A major outcome of the British Pharmacological Society’s ‘Focus on Pharmacology’ project has been a 2016 review of the Integrative Pharmacology Fund (IPF), a shared venture with AstraZeneca, GlaxoSmithKline, Pfizer, public funders and the Society to help support in vivo knowledge and skills. The impact of the £22m fund over its 12-year lifetime was evaluated and recommendations made for in vivo education, research and training. Drawing upon expertise from across the in vivo community, the Society and The Physiological Society co-hosted a workshop in November 2017 to discuss how these recommendations might be implemented. Future challenges arising from a changing scientific landscape were discussed as well as how best to nurture networks of good practice. Going forward, we will condense the outputs of these discussions and produce a report that will inform the necessary next steps for the in vivo community to ensure a sustainable and well-rounded future in vivo landscape.

Latest news & activity

Scholarship/studentship

The British Pharmacological Society is delighted to launch its PhD Funding Programme for awards in 2027.

The programme includes both the AJ Clark…

Prizes and awards

The Federation of European Pharmacological Societies (EPHAR) has opened applications for its Young Investigators Award 2026. Two awards of €1,000 each…

Prizes and awards

The British Pharmacological Society (BPS) recognises the contributions to pharmacology made by our members and increases its impact on the discipline…